Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 11:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,785 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vaccines Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Self-Administered Nasal Influenza Feasibility Study

NCT01933048
View directory record Official record
Conditions
Influenza
Interventions
FluMist
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 49 Years
Enrollment
1,077 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
San Diego, California • Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Jun 10, 2026, 11:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS

NCT04071158
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
RSV Vaccine, Tdap, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
713 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
16
States / cities
Stockbridge, Georgia • Honolulu, Hawaii • Wichita, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2021 · Synced Jun 10, 2026, 11:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine

NCT02212990
View directory record Official record
Conditions
Fever
Interventions
Acetaminophen Arm, Placebo Arm, Ibuprofen Arm
Other
Lead sponsor
Duke University
Other
Eligibility
6 Months to 47 Months
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Jun 10, 2026, 11:28 AM EDT
Terminated Phase 3 Interventional Results available

COVID-19 3rd Dose Vaccine in Transplant Patients

NCT05047640
View directory record Official record
Conditions
Covid19
Interventions
BNT162b2 vaccine, JNJ-78436735 Vaccine
Biological
Lead sponsor
Giselle Guerra
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jun 10, 2026, 11:28 AM EDT
Completed Phase 2 Interventional

Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma

NCT00938223
View directory record Official record
Conditions
Melanoma
Interventions
4-peptide and 12-peptide melanoma vaccines
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Jun 10, 2026, 11:28 AM EDT
Completed Phase 1 Interventional

Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients

NCT00052182
View directory record Official record
Conditions
HIV Infections
Interventions
EP HIV-1090
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 22, 2007 · Synced Jun 10, 2026, 11:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations

NCT03617523
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, 2018-2019 formulation, Flublok Quadrivalent vaccine, 2018-2019 formulation, Fluzone High-Dose vaccine, 2018-2019 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
Bardstown, Kentucky • Metairie, Louisiana • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Jun 10, 2026, 11:28 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine (VEE C-84) as a Booster to VEE TC-83

NCT00582088
View directory record Official record
Conditions
Venezuelan Equine Encephalomyelitis
Interventions
VEE C-84
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2021
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Jun 10, 2026, 11:28 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection

NCT00124215
View directory record Official record
Conditions
Hepatitis C
Interventions
GI-5005
Biological
Lead sponsor
GlobeImmune
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
5
States / cities
Pasadena, California • Denver, Colorado • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2010 · Synced Jun 10, 2026, 11:28 AM EDT
Completed Not applicable Interventional Results available

Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant

NCT01852591
View directory record Official record
Conditions
Multiple Myeloma
Interventions
PCV 13
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Jun 10, 2026, 11:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects

NCT02508376
View directory record Official record
Conditions
Tuberculosis
Interventions
AP10-602, GLA-SE, ID93
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jun 10, 2026, 11:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products

NCT02242968
View directory record Official record
Conditions
Vaccines, Antiviral Agents, Immunologic Factors, Physiological Effects of Drugs, Anti-Infective Agents
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jun 10, 2026, 11:28 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy

NCT00503568
View directory record Official record
Conditions
Lung Cancer
Interventions
Ad100-gp96Ig-HLA A1
Biological
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Jun 10, 2026, 11:28 AM EDT
Completed Phase 2 Interventional Results available

The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

NCT04977479
View directory record Official record
Conditions
Systemic Allergic Reaction
Interventions
Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Placebo, Pfizer-BioNTech COVID-19 Vaccine, Bivalent
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 69 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Jun 10, 2026, 11:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults

NCT00488046
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2007 · Synced Jun 10, 2026, 11:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules

NCT04440176
View directory record Official record
Conditions
Meningococcal Vaccine
Interventions
MenABCWY, Saline
Biological
Lead sponsor
Pfizer
Industry
Eligibility
11 Years to 14 Years
Enrollment
309 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
20
States / cities
Mobile, Alabama • San Diego, California • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jun 10, 2026, 11:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults

NCT01263691
View directory record Official record
Conditions
Bacillus Anthracis (Anthrax) Infection
Interventions
BioThrax, AV7909 Formulation 1, AV7909 Formulation 2, AV7909 Formulation 3, AV7909 Formulation 4, Control
Biological · Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 50 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
3
States / cities
Miami, Florida • Raleigh, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Jun 10, 2026, 11:28 AM EDT
Completed Not applicable Interventional Results available

Behavioral Economics to Improve Flu Vaccination Using EHR Nudges

NCT06057727
View directory record Official record
Conditions
Behavior, Health, Flu, Flu Vaccination
Interventions
Pre-visit patient text messaging, Default pended order, Monthly peer comparison feedback, High risk bidirectional pre-visit text messaging
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years and older
Enrollment
80,039 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Jun 10, 2026, 11:28 AM EDT
Completed Not applicable Interventional

Testing the Use of Prompts to Increase Adolescent Immunization Rates

NCT01984125
View directory record Official record
Conditions
Vaccine Preventable Diseases, Meningococcal Disease, Human Papillomavirus, Pertussis, Influenza
Interventions
Point-of-Care Prompt
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
11 Years to 18 Years
Enrollment
7,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
22
States / cities
Little Rock, Arkansas • Wilmington, Delaware • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Jun 10, 2026, 11:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

ETEC Logistics Trial (TREK)

NCT00516659
View directory record Official record
Conditions
Diarrhea
Interventions
Heat-Labile Enterotoxin of Escherichia coli (LT), Placebo
Biological
Lead sponsor
Intercell USA, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
13
States / cities
Long Beach, California • Chicago, Illinois • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Jun 10, 2026, 11:28 AM EDT
Not listed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00085397
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
autologous dendritic cell-tumor fusion vaccine, gp100 antigen, therapeutic autologous dendritic cells
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2009 · Synced Jun 10, 2026, 11:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth

NCT00459316
View directory record Official record
Conditions
HIV Infections, Meningitis
Interventions
Quadrivalent meningococcal conjugate vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 24 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
35
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jun 10, 2026, 11:28 AM EDT
Completed Phase 2 Interventional

Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma

NCT00307710
View directory record Official record
Conditions
Lymphoma
Interventions
Trivalent Baculovirus-expressed Influenza HA vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Jun 10, 2026, 11:28 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00019448
View directory record Official record
Conditions
Stage IV Melanoma, Recurrent Melanoma
Interventions
gp100 antigen, interleukin-2
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Timeline
1998 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Jun 10, 2026, 11:28 AM EDT